Vif Proteins from Diverse Primate Lentiviral Lineages Use the Same Binding Site in APOBEC3G

Michael Letko, Icahn School of Medicine at Mount Sinai
Guido Silvestri, Emory University
Beatrice H. Hahn, University of Pennsylvania
Frederick Bibollet-Ruche, University of Pennsylvania
Omer Gokcumen, Harvard University
Viviana Simon, Icahn School of Medicine at Mount Sinai
Marcel Ooms, Icahn School of Medicine at Mount Sinai

Journal Title: Journal of Virology
Volume: Volume 87, Number 21
Publisher: American Society for Microbiology | 2013-11, Pages 11861-11871
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1128/JVI.01944-13
Permanent URL: https://pid.emory.edu/ark:/25593/s5t59

Final published version: http://dx.doi.org/10.1128/JVI.01944-13

Copyright information:
© 2013, American Society for Microbiology. All Rights Reserved.
Accessed February 5, 2020 4:05 AM EST
**Vif Proteins from Diverse Primate Lentiviral Lineages Use the Same Binding Site in APOBEC3G**

Michael Letko, Guido Silvestri, Beatrice H. Hahn, Frederick Bibollet-Ruche, Omer Gokcumen, Viviana Simon, Marcel Ooms

**ABSTRACT**

APOBEC3G (A3G) is a cytidine deaminase that restricts human immunodeficiency virus type 1 (HIV-1) and other lentiviruses. Most of these viruses encode a Vif protein that directly binds A3G and leads to its proteasomal degradation. Both Vif proteins of HIV-1 and African green monkey simian immunodeficiency virus (SIVagm) bind residue 128 of A3G. However, this position does not control the A3G degradation by Vif variants derived from HIV-2 and SIVmac, which both originated from SIV of sooty mangabey monkeys (SIVsmm), suggesting that the A3G binding site for Vif proteins of the SIVsmm/HIV-2 lineage differs from that of HIV-1. To map the SIVsmm Vif binding site of A3G, we performed immunoprecipitations of individual A3G domains, Vif/A3G degradation assays and a detailed mutational analysis of human A3G. We show that A3G residue 129, but not the adjacent position 128, confers susceptibility to degradation by SIVsmm Vif. An artificial A3G mutant, the P129D mutant, was resistant to degradation by diverse Vifs from HIV-1, HIV-2, SIVagm, and chimpanzee SIV (SIVcpz), suggesting a conserved lentiviral Vif binding site. Gorilla A3G naturally contains a glutamine (Q) at position 129, which makes its A3G resistant to Vifs from diverse lineages. We speculate that gorilla A3G serves as a barrier against SIVcpz strains. In summary, we show that Vif proteins from distinct lineages bind to the same A3G loop, which includes positions 128 and 129. The multiple adaptations within this loop among diverse primates underscore the importance of counteracting A3G in lentiviral evolution.

---

**MANY OLD WORLD PRIMATE SPECIES AMONG AFRICAN PRIMATES ARE NATURALLY INFECTED WITH THEIR OWN VERSION OF SIMIAN IMMUNODEFICIENCY VIRUS (SIV)**

The pandemic HIV-1 group M is believed to have originated from a single successful cross-species transmission event from SIV-infected chimpanzees to humans (2). Three additional transmission events of SIV from chimpanzees and gorillas resulted in nonpandemic HIV-1 groups N, O, and P (Fig. 1A) (3–5). In addition, SIV from naturally infected sooty mangabey monkeys (SIVsmm) was transmitted to humans on at least nine occasions, resulting in HIV-2 groups A through I (Fig. 1A) (6–8). SIVsmm has also been transmitted to Asian macaques in captivity, resulting in SIVmac (1). The pandemic HIV-1 group M is transmitted to humans by deaminating the viral DNA during reverse transcription, which subsequently becomes degraded or severely mutated (9–11). However, most lentiviruses encode the accessory protein Vif that mediates the proteasomal degradation of A3G (12–14). As a result of genetic conflicts between Vif and A3G, positive selection on both proteins has led to host-specific A3G/Vif adaptations (15–18). For example, Vifs from HIV-1 and SIV of African green monkeys (SIVagm) can efficiently degrade their cognate A3G but are unable to counteract human A3G. We thus considered the possibility that the Vif proteins of SIVsmm, HIV-2, and SIVmac strains use an A3G binding site that does not include position 128.

In this study, we show that residues at position 129 in A3G (adjacent to position 128) control Vif binding and mediate resistance to degradation by diverse Vifs from SIVsmm, HIV-2, HIV-1, and SIVagm lineages. A3G 129P is conserved among humans and most primates except gorillas. The gorilla A3G contains 129Q, which yields an A3G protein that is resistant to HIV-1 and other lentiviruses.
SIV Vif-mediated degradation. Thus, our data indicate that Vif proteins from diverse HIV/SIV lineages use the same binding site in A3G to mediate its degradation.

MATERIALS AND METHODS

Plasmids. The replication-competent molecular clones NL4-3 and NL4-3/H9004 Vif were provided by the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, National Institutes of Health NIH Reagent Program (28, 29). The SIVsmm PG molecular clone was a generous gift from Frank Kirchhoff, University of Ulm, Ulm, Germany. SIVsmm ΔVif was produced by digesting the full-length molecular clone with XcmI, gel purifying the digested plasmid, and religating the gel-purified product to introduce a large deletion into the Vif sequence.

Plasmids with Vif sequences (Table 1)(28, 30–38) were used as templates for PCR amplification with Vif primers, containing NotI and EcoRI restriction sites, specific for the 5′ and 3′ regions of each variant, respectively. A carboxy-terminal FLAG tag was added to all cloned Vif sequences by overlapping PCR. Amplicons were digested with NotI/EcoRI, and the coding regions of the subcloned Vifs were inserted into pCRV1 as previously described (39, 40) Site-directed mutagenesis of Vif was performed using overlapping PCR as described previously (39). The mutated constructs were cloned into pCRV1 vector and confirmed by sequencing. Primer sequences are available upon request.

NCBI reference sequence numbers for the Vifs used are U26942.1 (NL4-3 Vif), AF077017.1 (SIVsmm), U04005.1 (SIVagmSab), US88991.1 (SIVagmTAN), EF394356.1 (SIVcpzTAN1), EF394357.1 (SIVcpzTAN2), DQ373065.1 (SIVcpzEK505), DQ373064.1 (SIVcpzLB715), EF535994.1 (SIVcpzMB897), M76764.1 (SIVmac239).

Lowland gorilla untransformed fibroblasts were obtained from the Coriell Institute (catalog no. PR00950), and A3G was amplified from cDNA (SuperScript III first-strand synthesis kit; Invitrogen) using the primers 5′-TACAAGCTTATGACGYCTCAGTTCAGAAACACA (forward) and 5′-AACATCGTGATGGTAGTCTCCGTGATTGAGAGA ATGG (reverse). All A3G genes were C-terminally triple-hemagglutinin (3×HA) tagged and cloned as described previously (41). The African green monkey A3G expression plasmid was obtained from the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, National Institutes of Health (NIH) Reagent Program, and was used as a template for PCR amplification (33, 34). Sooty mangabey A3G was amplified from cDNA derived from peripheral blood mononuclear cells (PBMC) of two sooty mangabeys (provided by Guido Silvestri) using the

TABLE 1 Summary of the Vif variants used in this study

<table>
<thead>
<tr>
<th>Vif variant</th>
<th>HIV or SIV origin</th>
<th>Plasmid sourcea</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV-1 NL4-3</td>
<td>Human</td>
<td>NIH 114</td>
<td>28</td>
</tr>
<tr>
<td>SIVsmm (PBj)</td>
<td>Sooty mangabey monkey</td>
<td>NIH 2998</td>
<td>30</td>
</tr>
<tr>
<td>SIVsmm (PGm)</td>
<td>Sooty mangabey monkey</td>
<td>F. Kirchhoff</td>
<td>31</td>
</tr>
<tr>
<td>HIV-2 Rod</td>
<td>Human</td>
<td>NIH 207</td>
<td>32</td>
</tr>
<tr>
<td>SIVagm Sab</td>
<td>African green monkey</td>
<td>NIH 2614</td>
<td>33</td>
</tr>
<tr>
<td>SIVagm Tan</td>
<td>African green monkey</td>
<td>NIH 3444</td>
<td>34</td>
</tr>
<tr>
<td>SIVmac 239</td>
<td>Rhesus macaque</td>
<td>NIH 210</td>
<td>35</td>
</tr>
<tr>
<td>SIVgor</td>
<td>Gorilla</td>
<td>NIH 11722</td>
<td>36</td>
</tr>
<tr>
<td>SIVpts1 (Tan1)</td>
<td>Chimpanzee (Pan troglodytes schweinfurthii)</td>
<td>B. H. Hahn</td>
<td>37</td>
</tr>
<tr>
<td>SIVpts2 (Tan2)</td>
<td>Chimpanzee (Pan troglodytes schweinfurthii)</td>
<td>B. H. Hahn</td>
<td>37</td>
</tr>
<tr>
<td>SIVptt1 (EK505)</td>
<td>Chimpanzee (Pan troglodytes troglodytes)</td>
<td>B. H. Hahn</td>
<td>38</td>
</tr>
<tr>
<td>SIVptt2 (LB715)</td>
<td>Chimpanzee (Pan troglodytes troglodytes)</td>
<td>B. H. Hahn</td>
<td>38</td>
</tr>
<tr>
<td>SIVptt3 (MB897)</td>
<td>Chimpanzee (Pan troglodytes troglodytes)</td>
<td>B. H. Hahn</td>
<td>38</td>
</tr>
</tbody>
</table>

a NIH strains were obtained from the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, National Institutes of Health NIH Reagent Program.
primers 5′-GCCCTGGGAGGTCACTTTAAGGA and 5′-TGGTCTCAAC CCAGTTCTCGGCT for the first round of amplification and 5′-CTTTAAGGA stop site. PCR products were cloned using a Stratagene Blunt kit (Stratagene). Sooty mangabeys A3G haplotypes were amplified from SootyClona plasmids with PfuUltra II poly

merase (Stratagene). A carboxyl-terminal 3XHA tag was added to all cloned A3G sequences by overlapping PCR, followed by cloning into the PTTR600 expression plasmid (41). All DNA preparations were sequenced to confirm the integrity of the APOBEC3 sequences. NCBI reference sequence numbers for the A3G used are JN662548.1 (African green monkey), NP_068594.1 (human), and AH013828.1 (gorilla).

Culture of cell lines. HEK 293T and TZM-bl reporter cells were maintained in Dulbecco’s modified Eagle medium (Corning Cellgro) supplemented with 10% fetal bovine serum (FBS) and 100 U/ml penicillin-streptomycin. TZM-bl cells were provided by the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, National Institutes of Health NH Reagent Program (42).

Vif-mediated A3G degradation. HEK 293T cells were cotransfected with FLAG-tagged A3G expression vectors (100 ng) and increasing amounts of Vif pCRV1 expression plasmid (0, 2.5, 5, 10, 25, and 50 ng) and pCRV1 empty plasmid (total amount of pCRV1, 50 ng). The transfections were performed in a 24-well format using 3 mg/ml polyethylenimine (PEI; Polysciences, Inc.). Transfected cells were lysed 2 days post-transfection and analyzed by Western blotting.

Western blot analysis. Transfected 293T cells were lysed (1% sodium dodecyl sulfate [SDS], 50 mM Tris-Cl [pH 8.0], 150 mM NaCl, and 5 mM EDTA). Proteins were separated on 10% SDS-polyacrylamide gel electrophoresis (Invitrogen), transferred to a polyvinylidene difluoride (PVDF) membrane (Pierce), and probed with anti-HA monoclonal antibody from mice (Sigma). Membranes were subsequently incubated with horseradish peroxidase-conjugated secondary antibodies (Sigma), developed with SuperSignal West Femto (Pierce), and detected by using the ProteinSimple FluorChem E imaging system.

Renilla luciferase-based A3G degradation assay. Human A3G was C-terminally tagged with Renilla luciferase using standard overlapping PCR. HEK 293T cells in 24-well plates were transfected with 5 ng of the A3G-Renilla constructs and 60 ng of Vif expression plasmid. Twenty-four hours later, cells were lysed in 150 μl 1× Renilla-specific lysis buffer (Promega) for 10 min at room temperature. Lysates (20 μl) were transferred to black 96-well plates (Greiner), 75 μl diluted substrate (Promega) was added to each well, and luciferase activity was assayed on a Victor-3 1420 dodecyl sulfate [SDS], 50 mM Tris-HCl [pH 8.0], 150 mM NaCl, and 5 mM EDTA). Proteins were separated on 10% SDS-polyacrylamide gel electrophoresis (Invitrogen), transferred to a polyvinylidene difluoride (PVDF) membrane (Pierce), and probed with anti-HA monoclonal antibody from mice (Sigma). Membranes were subsequently incubated with horseradish peroxidase-conjugated secondary antibodies (Sigma), developed with SuperSignal West Femto (Pierce), and detected by using the ProteinSimple FluorChem E imaging system.

Assessment of viral infectivity using single-cycle infectivity assays. HA-tagged A3G expression vectors (50 ng) and FLAG-tagged Vif vectors (10 ng) were cotransfected with the HIV molecular clones NL4-3 WT and NL4-3ΔVif (500 ng) in 293T cells. The transfections were performed in a 24-well format using 3 mg/ml polyethylenimine (PEI; Polysciences, Inc.), and culture medium was replenished after 24 h. The supernatants were harvested 48 h after transfection and used to infect 104 TZM-bl cells/well in black 96-well plates. TZM-bl cells were infected in triplicate with 20 μl of cell-free viral supernatants. β-Galactosidase activity was measured at 48 h postinfection using a Galacto-Star system (Applied Biosystems), as described previously (39). The data from three independent transfections were used to calculate average values and standard deviations.

Coimmunoprecipitation. HEK 293T cells were cotransfected with FLAG-Vif expression plasmids (100 ng), HA-A3G expression plasmid (900 ng) and NL4-3ΔVif molecular clone (1,000 ng) in a 6-well format (2 μg DNA total). Different amounts of Vif and A3G were tested in order to determine the optimal Vif:A3G transfection ratio (1:1, 1:4, and 1:9). Cells were lysed 2 days posttransfection in a mild lysis buffer (0.5% Triton X-100 in 1× phosphate-buffered saline [PBS] supplemented with EDTA-free protease inhibitor cocktail; Roche), and the cell lysates were cleared at 14,000 × g for 10 min at 4°C. Cleared lysates were incubated with EZ-View anti-HA beads (Sigma) at 4°C for 2 h. Beads were washed 4 times in mild lysis buffer, followed by 4 additional washes in stringent lysis buffer (1% Triton X, 0.1% SDS, 500 mM NaCl in PBS supplemented with EDTA-free protease inhibitor cocktail; Roche). Proteins were eluted from the beads by boiling in lithium dodecyl sulfate (LDS) loading buffer (Sigma). Proteins were analyzed by Western blotting for Vif (FLAG), A3G (HA), and tubulin.

RESULTS

SIVsmm Vif efficiently degrades human A3G. Although the importance of A3G position 128 is well established for HIV-1 and SIVagm Vif binding and A3G degradation (19, 20, 22, 23), little is known about the SIVsmm and HIV-2 Vif binding site. We first performed an A3G degradation assay with a panel of diverse SIV, HIV-1, and HIV-2 Vifs. Most of the Vif variants tested, including SIVsmm, could efficiently degrade human A3G compared to the no-Vif control or the inactive Vif mutant C133S, which cannot bind cullin 5 (43–45) (Fig. 1C). In agreement with previous studies (16, 19–23), SIVagm Vif failed to degrade human A3G. Taken together, our experimental system is suitable for efficiently discriminating between active and inactive Vif proteins and shows that human A3G is efficiently degraded by SIVsmm Vif.

A3Gsmm variants all contain 128K and restrict SIVsmm ΔVif. Given that human A3G was efficiently degraded by SIVsmm Vif (Fig. 1C), we speculated that the residues at position 128 of A3Gsmm and human A3G must be similar. However, at the start of this study, no information on A3Gsmm sequences was available. We therefore cloned and sequenced A3G transcripts from peripheral blood mononuclear cells (PBMC) of two sooty mangabeys. We identified four different A3Gsmm transcript variants, all of which encoded a lysine at position 128, like A3Gagm (Fig. 2A). Interestingly, all four A3Gsmm variants started at a downstream start codon at position eight compared to the recently published A3Gsmm sequence (46) and the reference A3Gmac sequence (21).

We next performed single-cycle infectivity assays with SIVsmm and SIVsmm ΔVif to determine the antiviral potency of the A3Gsmm variants. Figure 2B shows that all four variants potently restrict SIVsmm ΔVif. Moreover, all four A3Gsmm variants were degraded with similar efficiency by SIVsmm Vif, resulting in complete rescue of viral infectivity (Fig. 2B).

We next explored the mode of A3Gsmm restriction by mutating the N-terminal, C-terminal, or both deaminase domains (Fig. 2C). Restriction of SIVsmm ΔVif was maintained upon mutation of the N-terminal A3G region but was largely lost when the C-terminal A3G domain or both deaminase domains were inactivated. These findings indicate that the C-terminal deaminase domain of A3Gsmm, much like in the human A3G, is essential for efficient lentiviral restriction (47–50).

SIVsmm Vif-mediated A3G degradation is unaffected by A3G residue 128. Our results show that SIVsmm efficiently degrades human A3G, despite the residue difference at position 128 between A3Gsmm and human A3G (Fig. 1C). This indicates that SIVsmm, similarly to HIV-2 and SIVmac, can degrade A3G independently of the residue at position 128 (21, 23).

To further explore the role of A3G position 128 in SIVsmm Vif-mediated degradation, we tested the efficiencies of different
lentiviral Vif variants (two different SIVsmm, HIV-2, SIVagm, and HIV-1 NL4-3 Vifs) to degrade human A3G, A3Gsmm, A3Gagm, and the corresponding variants in which position 128 was mutated to either a D or K. Figure 3 shows that SIVsmm and HIV-2 Vifs both efficiently degraded A3G proteins from humans, African green monkeys, and sooty mangabeys regardless of their 128 residue. Of note, SIVagm Vif degraded only A3G variants that contain K, whereas HIV-1 Vif specifically degraded A3G 128D variants. These data indicate that SIVsmm and HIV-2 Vif are able to counteract different A3G proteins irrespective of the identity of the residue at position 128.

SIVsmm Vif-mediated A3G degradation requires a region between A3G amino acid positions 122 and 148. We next investigated whether SIVsmm and HIV-2 Vifs are more tolerant to variation at position 128 or whether they use another region within A3G for binding. Precedents for other APOBEC3 binding sites being used by Vif exist: HIV-1 Vif binds the N-terminal domain of human A3G around position 128 (19, 20, 22, 23) but associates with the C-terminal domains of human A3D and human A3F to induce their proteasomal degradation (51–54).

To determine which A3G domain is utilized for SIVsmm bind-
ing, we performed coimmunoprecipitations with SIVsmm Vif and the full-length human A3G or its N- and C-terminal domains. We found that SIVsmm Vif specifically coimmunoprecipitates with full-length A3G and its N-terminal domain, suggesting that SIVsmm Vif binds to the N-terminal domain of human A3G (Fig. 4A).

In order to map the region of interaction more precisely, we established a rapid, quantitative, and sensitive degradation assay based on degradation of human A3G fused to Renilla luciferase at the C terminus. The A3G-luciferase fusion protein was stably expressed when transfected in the absence of Vif or cotransfected with the SIVsmm VifC133S mutant, which cannot bind cullin 5 (Fig. 4; high numbers of relative light units [RLU] indicate high levels of expression) (43–45). However, in the presence of SIVsmm Vif, A3G was degraded and luciferase expression was reduced (Fig. 4B). Since SIVsmm Vif fails to bind the C-terminal A3G domain (Fig. 4A), we constructed chimeras of the N-terminal and C-terminal domains, which were then tested for Renilla luciferase expression in the presence of SIVsmm Vif. The Renilla luciferase expression of most of these chimeras was not affected by SIVsmm Vif, indicating that they were resistant to Vif-mediated degradation (Fig. 4B). However, inclusion of N-terminal A3G residues 122 to 148 conferred sensitivity to SIVsmm Vif-mediated degradation, suggesting that this region contains a binding site for SIVsmm Vif (Fig. 4B).

Position 129 in human A3G affects SIVsmm Vif-mediated degradation. Our data imply that residues between positions 122 and 148 of human A3G are necessary and required for SIVsmm Vif degradation. This region includes the A3G loop containing position 128, which is important for HIV-1 and SIVagm Vif binding and degradation (19, 20, 22–24, 26, 27, 35, 56). We thus performed a comprehensive mutational analysis of this A3G loop by alanine-scanning mutagenesis of the residues between positions 126 and 130. We subsequently tested five mutants in the Renilla luciferase degradation assay (Fig. 5A). Cotransfection of the A3G-luciferase constructs with HIV-1 Vif showed that A3G containing 129A was as resistant to HIV-1 degradation as A3G containing 128K (control; Fig. 5B), an observation which is consistent with results from previous studies (19, 20, 22, 23). A3G 127A and 129A mutants displayed some resistance to SIVsmm-mediated degradation, albeit to a lesser degree than HIV-1 Vif (Fig. 5C). Interestingly, position 129 in human A3G has been described as conferring resistance to HIV-1 Vif-mediated degradation (25, 27).

We chose to focus next on position 129 for in-depth analysis, since A3G position 127 is part of the RNA binding domain, which also mediates packaging into virions (25, 26). We tested nine different residues with various biochemical properties (e.g., hydrophobic, polar, acidic, or basic) at this position within the human A3G luciferase fusion construct. Several residues resulted in resistance against SIVsmm Vif-mediated degradation, with the A3G mutant containing an acidic aspartic acid (D) at position 129 displaying the highest level of resistance (Fig. 5D). In summary, our data identify A3G position 129 as an important determinant for degradation by SIVsmm Vif.

Human A3G 129D is resistant to HIV-1, HIV-2, and SIV Vif-mediated degradation. We next analyzed the effect of the aspartic acid at A3G position 129 within full-length human A3G using degradation and infectivity assays. Increasing amounts of SIVsmm Vif (0, 10, 25, 50, or 100 ng) were cotransfected with A3G WT (100 ng), and Vif-mediated degradation was assessed by Western blotting 2 days posttransfection. SIVsmm Vif efficiently degraded human A3G, whereas A3G 129D was resistant to SIVsmm Vif degradation even at
high Vif levels, which indicates that 129D confers resistance to degradation (Fig. 6A).

Infectivity assays were performed using full-length infectious SIVsmm and SIVsmm Vif molecular clones transfected in the presence of increasing amounts of human wild-type A3G (A3G WT; 129 proline [P]) and A3G 129D. Assessment of viral infectivity showed that human A3G WT and A3G 129D both restrict SIVsmm Vif efficiently (Fig. 6B, left), indicating that 129D does not affect A3G activity in the absence of Vif. However, only the activity of A3G WT was counteracted by WT SIVsmm, while A3G 129D was fully resistant (Fig. 6B, right).

In order to determine the sensitivity of human A3G 129D to other Vif proteins, we performed infectivity assays with HIV-1 Vif complemented with a comprehensive panel of lentiviral Vifs in the presence of human A3G WT and A3G 129D. Assessment of viral infectivity showed that human A3G WT and A3G 129D both restrict SIVsmm Vif efficiently (Fig. 6C). However, only the activity of A3G WT was counteracted by WT SIVsmm, while A3G 129D was fully resistant (Fig. 6C, right).

In order to analyze the effect of residue 129Q on the antiviral activity of gorilla A3G, we cloned gorilla A3G and generated its Q129P mutant. We compared the sensitivity of the gorilla A3G to various lentiviral Vifs with the sensitivity of human A3G WT and its corresponding P129Q mutant. SIVgor Vif counteracted human A3G with an efficiency similar to that of most other Vifs (Fig. 7B, left). However, most Vifs failed to counteract gorilla A3G with the exception of SIVgor Vif itself (Fig. 7B, right). To exclude the possibility that other residue differences between hu-
man and gorilla A3G affected the resistance to Vif, we exchanged both 129 residues and tested their sensitivity to various Vif proteins. The gorilla Q129P mutant behaved like human A3G inasmuch as both were counteracted by all Vifs except SIVagm Vif (Fig. 7C, left). Conversely, introducing 129Q into human A3G mimicked the resistance pattern observed for gorilla A3G (Fig. 7C, right). A comparison of the same Vifs cotransfected with A3G 129D showed a resistance pattern similar to that observed with A3G 129Q (Fig. 7D). Taken together, these results indicate that residue 129Q in gorilla A3G confers resistance to a diverse panel of Vif proteins.

A3G 129Q confers resistance to divers SIVcpz Vifs. SIVgor originated from SIVcpz (36), but the SIVcpz Vif tested did not efficiently counteract gorilla A3G (Fig. 7C, right). A comparison of the same Vifs cotransfected with A3G 129D showed a resistance pattern similar to that observed with A3G 129Q (Fig. 7D). Taken together, these results indicate that residue 129Q in gorilla A3G confers resistance to a diverse panel of Vif proteins.

A3G 129Q confers resistance to divers SIVcpz Vifs. SIVgor originated from SIVcpz (36), but the SIVcpz Vif tested did not efficiently counteract gorilla A3G (Fig. 7C, right). A comparison of the same Vifs cotransfected with A3G 129D showed a resistance pattern similar to that observed with A3G 129Q (Fig. 7D). Taken together, these results indicate that residue 129Q in gorilla A3G confers resistance to a diverse panel of Vif proteins.

A3G 129Q confers resistance to divers SIVcpz Vifs. SIVgor originated from SIVcpz (36), but the SIVcpz Vif tested did not efficiently counteract gorilla A3G (Fig. 7C, right). A comparison of the same Vifs cotransfected with A3G 129D showed a resistance pattern similar to that observed with A3G 129Q (Fig. 7D). Taken together, these results indicate that residue 129Q in gorilla A3G confers resistance to a diverse panel of Vif proteins.
Vif/A3G ratio, with HIV-1, SIVsmm, and HIV-2 Vifs cotransfected with human A3G WT, human A3G 128K, human A3G 129D, and human A3G 129Q. HIV-1 Vif association was decreased for A3G 128K, 129D, and 129Q mutants compared to A3G WT, despite the lower expression levels of A3G (which was due to Vif-mediated A3G degradation) (Fig. 9B). SIVsmm and HIV-2 Vif association was reduced only for A3G 129D and 129Q, which corresponded well with their resistance to Vif-mediated degradation. Thus, the immunoprecipitation results show that human A3G 129D and human A3G 129Q escape Vif-mediated degradation because of reduced association with Vif.

**DISCUSSION**

HIV-1 and HIV-2 originated from SIV of chimpanzees and sooty mangabeys, respectively (2). Successful transmission of these simian viruses required adaptation to human restriction factors (2, 15, 17). The HIV-1 Vif binding site of A3G includes position 128 (19, 20, 22, 23), which constitutes a barrier between humans and African green monkeys. However, degradation by HIV-2 and SIVmac Vif proteins from the distinct SIVsmm lineage was unaffected by this position, raising the possibility that another binding site might be used (22, 23). Our data now show that this is not the case.

We find that residue 129 in human A3G confers resistance to Vif-mediated degradation and leads to reduced association to a panel of diverse Vif proteins, including SIVsmm, HIV-2, HIV-1, SIVcpz, and SIVagm Vifs. Our results suggest that HIV and SIV Vifs adapted differently to the various primate A3G variants, resulting in HIV-1 and SIVagm Vifs requiring certain residues at positions 128 and 129, whereas HIV-2 and SIVsmm Vifs interact only with position 129. SIVgor Vif binding, however, depends only on the residue at A3G position 128 (Fig. 9C). However, all of these diverse Vif proteins bind the same exposed loop in A3G.

Although most reports showed that A3G position 128 affected Vif binding directly (19, 20, 22), some reports speculated that Vif-mediated A3G degradation was affected post-Vif binding (23, 52). Our data indicate that Vif/A3G DNA ratios used in the immunoprecipitation experiments greatly affect the results (Fig. 9A). Moreover, Vif binding differences between A3G WT and A3G 128K mutants could be observed only at low Vif/A3G ratios (Fig. 9A). These DNA ratios also better reflect the actual DNA concentrations used in the degradation and infectivity assays. Indeed, a study showing that A3G position 128 did not affect Vif binding used more Vif than A3G expression plasmids (23), which, accord-
In our results, may lead to underestimation of the differences in Vif binding efficiencies. Of note, numerous other differences between the aforementioned immunoprecipitations exist, such as salt and detergent concentrations, which could also account for the discrepancy between studies.

In contrast to chimpanzees, who frequently hunt monkeys, gorillas are strict herbivores, suggesting that their risk of exposure to SIV from infected primates is limited (36, 37, 60). Our findings suggest that gorilla A3G resists degradation by most Vifs, effectively serving as a barrier to SIV transmission. Despite a low risk of exposure and Vif-resistant A3G, gorillas acquired SIVcpz once (36), implying that SIVcpz Vif must have bypassed gorilla A3G. Most of the SIVcpz Vif alleles tested in this study failed to efficiently counteract gorilla A3G (Fig. 8). However, two of the SIVcpz Vifs (SIVcpzPtt1 and SIVcpzPtt2) exhibited some infectivity in the presence of gorilla A3G (Fig. 8A), suggesting that the restriction is not absolute. It is possible that some SIVcpz strains exist that can naturally counteract gorilla A3G. Indeed, SIVcpzPts, which encode Vifs with minimal activity against gorilla A3G, were never transmitted to gorillas, although their natural habitats overlap. Furthermore, we lack information to comprehensively assess natural gorilla A3G variation (A3G sequences from only two gorillas exist). Based on the extensive A3G diversity observed in rhesus and sooty mangabeys, it is conceivable that A3G position 129 is polymorphic in certain gorillas, making them more susceptible to transmissions of SIV from chimpanzees.

As a result of adaptations to overcoming gorilla A3G 129Q, SIVgor Vif appears to have lost its specificity regarding position 129. In contrast, SIVmac Vif is the only Vif that efficiently degrades all A3G variants independently of specific residues at 128 and 129 (Fig. 6C). Possibly, SIVmac Vif binds a distinct A3G region outside the A3G loop containing positions 128 and 129. A recent study showed that Vif from SIV in mantled colobus monkeys (Colobus guereza) (SIVcol) shifted its A3G binding site away from A3G positions 128 and 129 as a result of an A3G insertion near position 60 (46). Interestingly, rhesus macaque A3G also contains an insertion at a similar A3G position (Fig. 2A), which could also have resulted in a shifted binding site in A3G.

Overall, our analysis demonstrates that Vif from HIV-1, HIV-2, and several SIV strains bind a common, conserved region within A3G. The requirement of diverse Vifs to bind the same A3G region could potentially make A3G a better drug target than Vif.

---

**FIG 8** A3G 129Q confers resistance to diverse SIVcpz Vifs. A panel of SIVcpz Vif expression plasmids were cotransfected with gorilla A3G WT (A) and gorilla A3G 129P (B) and the NL4-3 Vif molecular clone in 293T cells. Two days later, the supernatants were used to infect TZM-bl cells, and β-galactosidase activity was measured 2 days postinfection. Transfected 293T cells were lysed and analyzed by Western blotting. Pts1, SIVcpzTAN1; Pts2, SIVcpzTAN2; Ptt1, SIVcpzEK505; Ptt2, SIVcpzLB715; Ptt3, SIVcpzMB897.

**FIG 9** SIVsmm Vif binds human A3G position 129. (A) A total of 500 ng Vif and 500 ng A3G (1:1), 250 ng Vif and 750 ng A3G (1:4), and 100 ng Vif and 900 ng A3G (1:9) were used to cotransfect 293T cells. Cells were lysed in a gentle lysis buffer 2 days later, and the cleared lysates were incubated with anti-HA beads (Sigma) at 4°C for 2 h. Beads were thoroughly washed in lysis buffer and proteins were eluted by boiling in sample loading buffer. Proteins were analyzed by Western blotting for Vif (FLAG) and hA3G (HA). (B) A total of 100 ng Vif and 900 ng A3G plasmids (1:9) were transfected, and cell lysates were subjected to coimmunoprecipitation as described above. (C) The predicted structure for the NTD of hA3G was modeled with SwissModel using APOBEC3C as a reference (61). SIVgor Vif is sensitive only to variation at position 128, whereas HIV-1 and SIVagm Vif are sensitive to changes in both positions 128 and 129; HIV-2 and SIVsmm Vif interact only with position 129.

---

November 2013 Volume 87 Number 21 jvi.asm.org
itself, which is more variable and will quickly adapt leading to drug resistance. Structural information on the A3G-Vif interface will help define specific residues involved in this interaction leading to the identification of important A3G structural elements likely encompassing position 129 in A3G.

ACKNOWLEDGMENTS

We thank F. Kirchhoff for providing the SIVsmm GPG full-length molecular clone. We also kindly thank V. Pathak for productive discussions.

This work was funded in part by NIH grants R01 AI089246 (V.S.), R01 AI064001 (V.S.), R37 AI50529 (B.H.H.), R01 AI58715 (B.H.H.), and R37 AI66998 (G.S.) and Public Health Service Institutional Research Training Award T32AI07647 (M.L.).

REFERENCES


